Susceptibility to hyperglycemia in patients with chronic kidney disease

American Journal of Nephrology

Volumn 29, Issue 5, 2009, Pages 406-413

  Shehab Eldin, Walid ^a   Zaki, Ali ^a   Gazareen, Sanaa ^a   Shoker, Ahmed ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adiponectin; Hyperglycemia; Inflammation; Insulin resistance; Kidney diseases; Reactive oxygen species

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; MALONALDEHYDE; PROINSULIN;

ARTICLE; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PREVALENCE; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; SASKATCHEWAN;

EID: 55449115121     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000171379     Document Type: Article

References (34)

1. Shehab Eldin W, Ragheb A, Klassen J, Shoker A: Evidence for increased risk of prediabetes in the uremic patient. Nephron Clin Pract 2007;108:c47-c55.
2. Sui Y, Zhao HL, Ma RC, Ho CS, Kong AP, Lai FM, Ng HK, Rowlands DK, Chan JC, Tong PC: Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. Cell Mol Life Sci 2007;64:3119-3128.
3. DeFronzo RA, Tobin JD, Rowe JW, Andres R: Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978;62:425-435.
4. Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME: The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther 2006;23:988-998.
5. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16:1091-1098.
6. Hayden MR, Tyagi SC: Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 2002;3:86-108.
7. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48: 752-760.
8. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R, Stepan H: Circulating high-molecular-weight adiponectin is up-regulated in preeclampsia and is related to insulin sensitivity and renal function. Eur J Endocrinol 2008;158:197-201.
9. Maeda N, Shimomura I: Adiponectin: anti-diabetic, anti-atherosclerotic and anti-inflammatory adipocytokine. Cell Technol 2005;24:449-455.
10. American Diabetes Association (ADA): Clinical practice recommendations. Diabetes Care 2007;30:S3.
11. El Ghar SM, Qureshi M, Shoker A, Prasad K: Oxidative stress in renal transplant patients who develop cardiovascular disease. J Cardiovasc Pharmacol Ther 2006;11:203-210.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Di-abetologia 1985;28:412-419.
13. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes 1989; 38:1333-1336.
14. Bagust A, Beale S: Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003;96:281-288.
15. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-2974.
16. Alvestrand A, Mujagic M, Wajngot A, Efendic S: Glucose intolerance in uremic patients: the relative contributions of impaired beta-cell function and insulin resistance. Clin Nephrol 1989;31:175-183.
17. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-1347.
18. Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T: Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. Clin Nephrol 2000; 54: 366-373.
19. Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP, Campbell SE, Steffes MW: Standardization of insulin im-munoassays: report of the American Diabetes Association Workgroup. Clin Chem 2007;53:711-716.
20. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 1981;67:563-568.
21. Satirapoj B, Supasyndh O, Boonyavarakul A, Luesutthiviboon L, Choovichian P: The correlation of insulin resistance and renal function in non diabetic chronic kidney disease patients. J Med Assoc Thai 2005;88(suppl 3): S97-S104.
22. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003;26: 1745-1751.
23. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I: CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 2008; 129:815-822.
24. Saisho Y, Hirose H, Yamamoto Y, Nakatani H, Itoh H: Combination of C-reactive protein and high molecular weight (HMW) adiponectin reflects further metabolic abnormalities compared with each of them alone in Japanese type 2 diabetic subjects. Endocr J 2008;55:331-338.
25. Tabara Y, Osawa H, Kawamoto R, Tachiba-na-Iimori R, Yamamoto M, Nakura J, Miki T, Makino H, Kohara K: Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are syn-ergistic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: the Shimanami Health Promoting Program Study. J Clin Endocrinol Metab 2008;93:715-722.
26. Pepys MB: C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol 2008;4:234-235.
27. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetolo-gia2002;45:85-96.
28. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
29. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-58.
30. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
31. Stefan N, Stumvoll M, Vozarova B, Weyer C, Funahashi T, Matsuzawa Y, Bogardus C, Tataranni PA: Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003;26:3315-3319.
32. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thia-zolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
33. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
34. Vasseur F, Lepretre F, Lacquemant C, Froguel P: The genetics of adiponectin. Curr Diab Rep 2003;3:151-158.